Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Skelet Muscle ; 8(1): 28, 2018 08 28.
Article in English | MEDLINE | ID: mdl-30153853

ABSTRACT

BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So far, more than 40 dominant pathogenic mutations have been described leading to several phenotypes many of which are associated with a mis-localization of the mutant protein to the Golgi. Golgi retention and endoplasmic reticulum (ER) stress has been demonstrated for the CAV3 p.P104L mutation, but further downstream pathophysiological consequences remained elusive so far. METHODS: We utilized a transgenic (p.P104L mutant) mouse model and performed proteomic profiling along with immunoprecipitation, immunofluorescence and immunoblot examinations (including examination of α-dystroglycan glycosylation), and morphological studies (electron and coherent anti-Stokes Raman scattering (CARS) microscopy) in a systematic investigation of molecular and subcellular events in p.P104L caveolinopathy. RESULTS: Our electron and CARS microscopic as well as immunological studies revealed Golgi and ER proliferations along with a build-up of protein aggregates further characterized by immunoprecipitation and subsequent mass spectrometry. Molecular characterization these aggregates showed affection of mitochondrial and cytoskeletal proteins which accords with our ultra-structural findings. Additional global proteomic profiling revealed vulnerability of 120 proteins in diseased quadriceps muscle supporting our previous findings and providing more general insights into the underlying pathophysiology. Moreover, our data suggested that further DGC components are altered by the perturbed protein processing machinery but are not prone to form aggregates whereas other sarcolemmal proteins are ubiquitinated or bind to p62. Although the architecture of the ER and Golgi as organelles of protein glycosylation are altered, the glycosylation of α-dystroglycan presented unchanged. CONCLUSIONS: Our combined data classify the p.P104 caveolinopathy as an ER-Golgi disorder impairing proper protein processing and leading to aggregate formation pertaining proteins important for mitochondrial function, cytoskeleton, ECM remodeling and sarcolemmal integrity. Glycosylation of sarcolemmal proteins seems to be normal. The new pathophysiological insights might be of relevance for the development of therapeutic strategies for caveolinopathy patients targeting improved protein folding capacity.


Subject(s)
Caveolin 3/metabolism , Muscle, Skeletal/metabolism , Muscular Dystrophies, Limb-Girdle/genetics , Mutation , Animals , Caveolin 3/genetics , Cytoskeleton/metabolism , Endoplasmic Reticulum Stress , Extracellular Matrix/metabolism , Humans , Mice , Muscle, Skeletal/ultrastructure , Muscular Dystrophies, Limb-Girdle/pathology , Protein Processing, Post-Translational , Proteome/genetics , Proteome/metabolism , Sarcolemma/metabolism
2.
Orphanet J Rare Dis ; 13(1): 70, 2018 05 02.
Article in English | MEDLINE | ID: mdl-29720219

ABSTRACT

GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field provided valuable knowledge through natural history studies, patient registries and clinical trial, which significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are summarising current GNE myopathy, scientific trends and open questions, which would be of significant interest for a wide neuromuscular diseases community.


Subject(s)
Distal Myopathies/genetics , Distal Myopathies/pathology , Animals , Distal Myopathies/drug therapy , Humans , Muscle Weakness/drug therapy , Muscle Weakness/genetics , Muscle Weakness/pathology , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , N-Acetylneuraminic Acid/therapeutic use , Research Design
3.
Muscle Nerve ; 57(3): 380-387, 2018 03.
Article in English | MEDLINE | ID: mdl-29053898

ABSTRACT

INTRODUCTION: Earlier small case series and clinical observations reported on chronic pain playing an important role in facioscapulohumeral dystrophy (FSHD). The aim of this study was to determine the characteristics and impact of pain on quality of life (QoL) in patients with FSHD. METHODS: We analyzed patient reported outcome measures collected through the U.K. FSHD Patient Registry. RESULTS: Of 398 patients, 88.6% reported pain at the time of study. The most frequent locations were shoulders and lower back. A total of 203 participants reported chronic pain, 30.4% of them as severe. The overall disease impact on QoL was significantly higher in patients with early onset and long disease duration. Chronic pain had a negative impact on all Individualised Neuromuscular Quality of Life Questionnaire domains and overall disease score. DISCUSSION: Our study shows that pain in FSHD type 1 (FSHD1) is frequent and strongly impacts on QoL, similar to other chronic, painful disorders. Management of pain should be considered when treating FSHD1 patients. Muscle Nerve 57: 380-387, 2018.


Subject(s)
Chronic Pain/psychology , Muscular Dystrophy, Facioscapulohumeral/psychology , Quality of Life/psychology , Adult , Aged , Chronic Pain/complications , Chronic Pain/diagnosis , Female , Humans , Male , Middle Aged , Muscular Dystrophy, Facioscapulohumeral/complications , Muscular Dystrophy, Facioscapulohumeral/diagnosis , Pain Measurement , Severity of Illness Index , Young Adult
4.
J Neuromuscul Dis ; 3(2): 169-181, 2016 05 27.
Article in English | MEDLINE | ID: mdl-27854219

ABSTRACT

Chaperone dysfunction leading to the build-up of misfolded proteins could frequently be linked to clinical manifestations also affecting the nervous system and the skeletal muscle. In addition, increase in chaperone function is beneficial to antagonize protein aggregation and thus represents a promising target for therapeutic concepts for many genetic and acquired chaperonopathies. However, little is known on the precise molecular mechanisms defining the cell and tissue abnormalities in the case of impaired chaperone function as well as on underlying effects in the case of compensatory up-regulation of chaperones. This scarcity of knowledge often arises from a lack of appropriate animal models that mimic closely the human molecular, cellular, and histological characteristics. Here, we introduce the Sil1-mutant woozy mouse as a suitable model to investigate molecular and cellular mechanisms of impaired ER-chaperone function affecting the integrity of nervous system and skeletal muscle. The overlapping clinical findings in man and mouse indicate that woozy is a good copy of a human phenotype called Marinesco-Sjögren syndrome. We confirm the presence of ER-stress and expand the biochemical knowledge of altered nuclear envelope in muscle, a hallmark of SIL1-disease. In addition, our data suggest that impaired excitation-contraction coupling might be part of the SIL1-pathophysiology. Our results moreover indicate that divergent expression of pro- and anti-survival proteins is decisive for Purkinje cell survival. By summarizing the current knowledge of woozy, we focus on the suitability of this animal model to study neuroprotective co-chaperone function and to investigate the involvement of co-chaperones in the predisposition of other disorders such as diabetic neuropathy.


Subject(s)
Disease Models, Animal , Endoplasmic Reticulum Stress/genetics , Endoplasmic Reticulum/metabolism , Guanine Nucleotide Exchange Factors/genetics , Mice , Molecular Chaperones , Spinocerebellar Degenerations/genetics , Animals , Cell Survival , Cerebellum/pathology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscle, Skeletal/ultrastructure , Mutation , Nuclear Envelope/metabolism , Purkinje Cells/metabolism , Spinocerebellar Degenerations/metabolism , Spinocerebellar Degenerations/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...